ENTROPY NEURODYNAMICS LIMITED — Director's Dealing 2020

Dec 22, 2020

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity:Exopharm Limited
ABN:78 163 765 991

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mr Jason M Watson
Date of last notice	10 November 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Part 1 - Change of director’s relevant interests in	Part 1 - Change of director’s relevant interests in	securities	securities	securities
In the case of a trust, this includes interests in the trustNote: In the case of a company, interests which come within p		made available by the responsible entity of the trustaragraph (i) of the definition of “notifiable interest of a director” shou
be disclosed in this part.Direct or indirect interestNature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to theinterest.Date of changeNo. of securities held prior to changeClassNumber acquired
	Direct or indirect interest		Indirect
	Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to theinterest.	relevant	Watson Practice Company Pty Ltd <WatsonA/C> (Director and Controller)	Practice
	Date of change		22 December 2020
	No. of securities held prior to change		290,000 Fully Paid Ordinary Shares90,000 Unlisted Performance Rights
	Class		Fully Paid Ordinary Shares
	Number acquired		60,000
	Number disposed		Nil
	Value/Consideration		$0.3275 per Fully Paid Ordinary Share
	Note: If consideration is non-cash, provide details and esvaluation	timated
	No. of securities held after change		350,000 Fully Paid Ordinary Shares
			90,000 Unlisted Performance Rights

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change

Off-market trade

Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

==> picture [434 x 317] intentionally omitted <==

----- Start of picture text ----- Detail of contract N/ANature of interest N/AName of registered holder N/A(if issued securities)Date of change N/ANo. and class of securities to which N/Ainterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changedInterest acquired N/AInterest disposed N/AValue/Consideration N/ANote: If consideration is non-cash, provide detailsand an estimated valuationInterest after change N/A----- End of picture text -----

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011